KRAKOW, Poland, January 2,
2019 /PRNewswire/ --
Selvita (WSE: SLV), a clinical stage
drug discovery and development company engaged in the research and
development of novel cancer therapies, today announced that Chief
Executive Officer Pawel Przewiezlikowski will present a
corporate overview at the Biotech Showcase 2019 conference
taking place Jan. 7-9 in San Francisco.
Details of the presentation are as
follows:
Date: Monday, January 7, 2019
Time: 4:30 p.m. PST
Room: Franciscan A (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333
O'Farrell Street
About Biotech Showcase
Biotech Showcase™ is an investor and
networking conference devoted to providing private and public
biotechnology and life sciences companies with an opportunity to
present to, and meet with, investors and pharmaceutical executives
in one place during the course of one of the industry's largest
annual healthcare investor conferences. Investors and
biopharmaceutical executives from around the world gather in
San Francisco during this
bellwether week which sets the tone for the coming year. Now in its
eleventh year, this rapidly growing conference features multiple
tracks of presenting companies, plenary sessions, workshops,
networking, and an opportunity to schedule one-to-one meetings.
Biotech Showcase is produced by Demy-Colton and EBD Group. Both
organizations have a long history of producing high quality
programs that support the biotechnology and broader life sciences
industry.
To contact Selvita's delegates at this
conference, please contact us at: magdalena.marciniak@selvita.com ,
or +48-539-939-584.
About Selvita
Selvita is developing novel small
molecule therapies that address emerging targets in oncology with
industry-leading research expertise supported by a research
services division. Pipeline candidates apply diverse mechanisms
directed at kinases, synthetic lethality pathways, immuno-oncology
pathways and other cancer-related targets. SEL24 is a dual PIM/FLT3
kinase inhibitor licensed to the Menarini Group in clinical
development for the treatment of acute myeloid leukemia. SEL120 is
a CDK8 kinase inhibitor with potential for development in
indications including hematological malignancies and solid tumors.
Selvita is headquartered in Krakow
with offices in the U.S. and U.K.
Contact:
Julia Balanova (investors)
+1-646-378-2936
jbalanova@troutgroup.com
Rich
Allan (media)
+1-646-378-2958
rallan@troutgroup.com
SOURCE Selvita